<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35390742</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-5586</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>28</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neoplasia (New York, N.Y.)</Title>
          <ISOAbbreviation>Neoplasia</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction.</ArticleTitle>
        <Pagination>
          <StartPage>100785</StartPage>
          <MedlinePgn>100785</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">100785</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neo.2022.100785</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1476-5586(22)00014-8</ELocationID>
        <Abstract>
          <AbstractText>In multiple myeloma (MM), communication via Notch signaling in the tumor niche stimulates tumor progression and bone destruction. We previously showed that osteocytes activate Notch, increase Notch3 expression, and stimulate proliferation in MM cells. We show here that Notch3 inhibition in MM cells reduced MM proliferation, decreased Rankl expression, and abrogated the ability of MM cells to promote osteoclastogenesis. Further, Notch3 inhibition in MM cells partially prevented the Notch activation and increased proliferation induced by osteocytes, demonstrating that Notch3 mediates MM-osteocyte communication. Consistently, pro-proliferative and pro-osteoclastogenic pathways were upregulated in CD138<sup>+</sup> cells from newly diagnosed MM patients with high vs. low NOTCH3 expression. These results show that NOTCH3 signaling in MM cells stimulates proliferation and increases their osteoclastogenic potential. In contrast, Notch2 inhibition did not alter MM cell proliferation or communication with osteocytes. Lastly, mice injected with Notch3 knock-down MM cells had a 50% decrease in tumor burden and a 50% reduction in osteolytic lesions than mice bearing control MM cells. Together, these findings identify Notch3 as a mediator of cell communication among MM cells and between MM cells and osteocytes in the MM tumor niche and warrant future studies to exploit Notch3 as a therapeutic target to treat MM.</AbstractText>
          <CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sabol</LastName>
            <ForeName>Hayley M</ForeName>
            <Initials>HM</Initials>
            <AffiliationInfo>
              <Affiliation>Physiology and Cell Biology, University of Arkansas for Medical Sciences, Little Rock, AR, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amorim</LastName>
            <ForeName>Tânia</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Medicine, Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ashby</LastName>
            <ForeName>Cody</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, United States; Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Halladay</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Medicine, Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Anderson</LastName>
            <ForeName>Judith</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Medicine, Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cregor</LastName>
            <ForeName>Meloney</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Physiology and Cell Biology, University of Arkansas for Medical Sciences, Little Rock, AR, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sweet</LastName>
            <ForeName>Megan</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Medicine, Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nookaew</LastName>
            <ForeName>Intawat</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, United States; Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kurihara</LastName>
            <ForeName>Noriyoshi</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Medicine, Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Roodman</LastName>
            <ForeName>G David</ForeName>
            <Initials>GD</Initials>
            <AffiliationInfo>
              <Affiliation>Medicine, Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bellido</LastName>
            <ForeName>Teresita</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Physiology and Cell Biology, University of Arkansas for Medical Sciences, Little Rock, AR, United States; Central Arkansas Veterans Healthcare System, Little Rock, AR, United States; Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Delgado-Calle</LastName>
            <ForeName>Jesus</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Physiology and Cell Biology, University of Arkansas for Medical Sciences, Little Rock, AR, United States; Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, United States. Electronic address: jdelgadocalle@uams.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P20 GM125503</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA241677</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA209882</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R37 CA251763</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AR059357</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neoplasia</MedlineTA>
        <NlmUniqueID>100886622</NlmUniqueID>
        <ISSNLinking>1476-5586</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C499374">NOTCH3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071656">Receptor, Notch3</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002450" MajorTopicYN="Y">Cell Communication</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009101" MajorTopicYN="Y">Multiple Myeloma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010011" MajorTopicYN="Y">Osteocytes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010012" MajorTopicYN="N">Osteogenesis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010014" MajorTopicYN="Y">Osteolysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071656" MajorTopicYN="Y">Receptor, Notch3</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Bone</Keyword>
        <Keyword MajorTopicYN="N">Cancer</Keyword>
        <Keyword MajorTopicYN="N">Myeloma</Keyword>
        <Keyword MajorTopicYN="N">Notch</Keyword>
        <Keyword MajorTopicYN="N">Osteocytes</Keyword>
        <Keyword MajorTopicYN="N">Tumor microenvironment</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>20</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35390742</ArticleId>
        <ArticleId IdType="pmc">PMC8990177</ArticleId>
        <ArticleId IdType="doi">10.1016/j.neo.2022.100785</ArticleId>
        <ArticleId IdType="pii">S1476-5586(22)00014-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Rajkumar S.V. Myeloma today: Disease definitions and treatment advances. Am. J. Hematol. 2016;91:90–100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4715763</ArticleId>
            <ArticleId IdType="pubmed">26565896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terpos E., Berenson J., Raje N., Roodman G.D. Management of bone disease in multiple myeloma. Expert Rev. Hematol. 2014;7:113–125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24433088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lomas O.C., Tahri S., Ghobrial I.M. The microenvironment in myeloma. Curr. Opin. Oncol. 2020;32:170–175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31895122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meurette O., Mehlen P. Notch signaling in the tumor microenvironment. Cancer Cell. 2018;34:536–548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30146333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabol H.M., Delgado-Calle J. The multifunctional role of Notch signaling in multiple myeloma. J. Cancer Metast. Treat. 2021;7:20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8589324</ArticleId>
            <ArticleId IdType="pubmed">34778567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delgado-Calle J., Anderson J., Cregor M.D., Hiasa M., Chirgwin J.M., Carlesso N., Yoneda T., Mohammad K.S., Plotkin L.I., Roodman G.D., Bellido T. Bidirectional notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma. Cancer Res. 2016;76:1089–1100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4775415</ArticleId>
            <ArticleId IdType="pubmed">26833121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colombo M., Galletti S., Bulfamante G., Falleni M., Tosi D., Todoerti K., Lazzari E., Crews L.A., Jamieson C.H., Ravaioli S., Baccianti F., Garavelli S., Platonova N., Neri A., Chiaramonte R. Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche. Oncotarget. 2016;7:56013–56029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5302893</ArticleId>
            <ArticleId IdType="pubmed">27463014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo D., Li C., Teng Q., Sun Z., Li Y., Zhang C. Notch1 overexpression promotes cell growth and tumor angiogenesis in myeloma. Neoplasma. 2013;60:33–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23067214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiron D., Maiga S., Descamps G., Moreau P., Le G.S., Marionneau S., Ouiller T., Moreaux J., Klein B., Bataille R., Amiot M., Pellat-Deceunynck C. Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. Blood Cells Mol. Dis. 2012;48:247–253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22341562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu D., Hu J., Xu S., De B.E., Menu E., Van C.B., Vanderkerken K., Van V.E. Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation. Leukemia. 2012;26:1402–1405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22094583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabol H.M., Ferrari A.J., Adhikari M., Amorim T., McAndrews K., Anderson J., Vigolo M., Lehal R., Cregor M., Khan S., Cuevas P.L., Helms J.A., Kurihara N., Srinivasan V., Ebetino F.H., Boeckman R.K., Jr., Roodman G.D., Bellido T., Delgado-Calle J. Targeting notch inhibitors to the myeloma bone marrow niche decreases tumor growth and bone destruction without gut toxicity. Cancer Res. 2021;81:5102–5114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8488008</ArticleId>
            <ArticleId IdType="pubmed">34348968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwarzer R., Nickel N., Godau J., Willie B.M., Duda G.N., Schwarzer R., Cirovic B., Leutz A., Manz R., Bogen B., Dorken B., Jundt F. Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model. Blood Cancer J. 2014;4:e217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4080208</ArticleId>
            <ArticleId IdType="pubmed">24927406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li M., Chen F., Clifton N., Sullivan D.M., Dalton W.S., Gabrilovich D.I., Nefedova Y. Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect. Mol. Cancer Ther. 2010;9:3200–3209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3058809</ArticleId>
            <ArticleId IdType="pubmed">21159606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramakrishnan V., Ansell S., Haug J., Grote D., Kimlinger T., Stenson M., Timm M., Wellik L., Halling T., Rajkumar S.V., Kumar S. MRK003, a gamma-secretase inhibitor exhibits promising in vitro preclinical activity in multiple myeloma and non-Hodgkin’s lymphoma. Leukemia. 2012;26:340–348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4384189</ArticleId>
            <ArticleId IdType="pubmed">21826062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imbimbo B.P. Therapeutic potential of gamma-secretase inhibitors and modulators. Curr. Top. Med. Chem. 2008;8:54–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18220933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Searfoss G.H., Jordan W.H., Calligaro D.O., Galbreath E.J., Schirtzinger L.M., Berridge B.R., Gao H., Higgins M.A., May P.C., Ryan T.P. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J. Biol. Chem. 2003;278:46107–46116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12949072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colombo M., Galletti S., Garavelli S., Platonova N., Paoli A., Basile A., Taiana E., Neri A., Chiaramonte R. Notch signaling deregulation in multiple myeloma: A rational molecular target. Oncotarget. 2015;6:26826–26840.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4694956</ArticleId>
            <ArticleId IdType="pubmed">26308486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delgado-Calle J., Bellido T. The osteocyte as a signaling cell. Physiol. Rev. 2022;102:379–410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8858675</ArticleId>
            <ArticleId IdType="pubmed">34337974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nefedova Y., Cheng P., Alsina M., Dalton W.S., Gabrilovich D.I. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood. 2004;103:3503–3510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14670925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patro R., Duggal G., Love M.I., Irizarry R.A., Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods. 2017;14:417–419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5600148</ArticleId>
            <ArticleId IdType="pubmed">28263959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Love M.I., Huber W., Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4302049</ArticleId>
            <ArticleId IdType="pubmed">25516281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taron M., Rosell R., Felip E., Mendez P., Souglakos J., Ronco M.S., Queralt C., Majo J., Sanchez J.M., Sanchez J.J., Maestre J. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum. Mol. Genet. 2004;13:2443–2449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15317748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shalapour S., Hof J., Kirschner-Schwabe R., Bastian L., Eckert C., Prada J., Henze G., von Stackelberg A., Seeger K. High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse. Haematologica. 2011;96:1627–1635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3208680</ArticleId>
            <ArticleId IdType="pubmed">21828124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schuster S.R., Kortuem K.M., Zhu Y.X., Braggio E., Shi C.X., Bruins L.A., Schmidt J.E., Ahmann G., Kumar S., Rajkumar S.V., Mikhael J., Laplant B., Champion M.D., Laumann K., Barlogie B., Fonseca R., Bergsagel P.L., Lacy M., Stewart A.K. The clinical significance of cereblon expression in multiple myeloma. Leuk. Res. 2014;38:23–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3905958</ArticleId>
            <ArticleId IdType="pubmed">24129344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooper L.A., Gutman D.A., Chisolm C., Appin C., Kong J., Rong Y., Kurc T., Van Meir E.G., Saltz J.H., Moreno C.S., Brat D.J. The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am. J. Pathol. 2012;180:2108–2119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3354586</ArticleId>
            <ArticleId IdType="pubmed">22440258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varemo L., Nielsen J., Nookaew I. Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods. Nucleic. Acids. Res. 2013;41:4378–4391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3632109</ArticleId>
            <ArticleId IdType="pubmed">23444143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellido T., Delgado-Calle J. Ex vivo organ cultures as models to study bone biology. JBMR Plus. 2020;4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7059827</ArticleId>
            <ArticleId IdType="pubmed">32161838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delgado-Calle J., Kurihara N., Atkinson E.G., Nelson J., Miyagawa K., Galmarini C.M., Roodman G.D., Bellido T. Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts. Oncotarget. 2019;10:2709–2721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6505631</ArticleId>
            <ArticleId IdType="pubmed">31105871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kyle R.A., Rajkumar S.V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2627786</ArticleId>
            <ArticleId IdType="pubmed">18971951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dallas S.L., Garrett I.R., Oyajobi B.O., Dallas M.R., Boyce B.F., Bauss F., Radl J., Mundy G.R. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood. 1999;93:1697–1706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10029599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garrett I.R., Dallas S., Radl J., Mundy G.R. A murine model of human myeloma bone disease. Bone. 1997;20:515–520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9177864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radl J., Croese J.W., Zurcher C., Van den Enden-Vieveen M.H., de Leeuw A.M. Animal model of human disease. Multiple myeloma. Am. J. Pathol. 1988;132:593–597.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1880745</ArticleId>
            <ArticleId IdType="pubmed">3414786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsunenari T., Koishihara Y., Nakamura A., Moriya M., Ohkawa H., Goto H., Shimazaki C., Nakagawa M., Ohsugi Y., Kishimoto T., Akamatsu K. New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor. Blood. 1997;90:2437–2444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9310495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delgado-Calle J., Anderson J., Cregor M.D., Condon K.W., Kuhstoss S.A., Plotkin L.I., Bellido T., Roodman G.D. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. Leukemia. 2017;31:2686–2694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5699973</ArticleId>
            <ArticleId IdType="pubmed">28529307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petrusca D.N., Toscani D., Wang F.M., Park C., Crean C.D., Anderson J.L., Marino S., Mohammad K.S., Zhou D., Silbermann R., Sun Q., Kurihara N., Galson D.L., Giuliani N., Roodman G.D. Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis. J. Hematol. Oncol. 2018;11:123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6172782</ArticleId>
            <ArticleId IdType="pubmed">30286780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asosingh K., Radl J., Van Riet I., Van Camp B., Vanderkerken K. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol. J. 2000;1:351–356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11920212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hosseini-Alghaderi S., Baron M. Notch3 in development, health and disease. Biomolecules. 2020;10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7175233</ArticleId>
            <ArticleId IdType="pubmed">32210034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aster J.C., Pear W.S., Blacklow S.C. The varied roles of notch in cancer. Annu. Rev. Pathol. 2017;12:245–275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5933931</ArticleId>
            <ArticleId IdType="pubmed">27959635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colombo M., Thummler K., Mirandola L., Garavelli S., Todoerti K., Apicella L., Lazzari E., Lancellotti M., Platonova N., Akbar M., Chiriva-Internati M., Soutar R., Neri A., Goodyear C.S., Chiaramonte R. Notch signaling drives multiple myeloma induced osteoclastogenesis. Oncotarget. 2014</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4279381</ArticleId>
            <ArticleId IdType="pubmed">25257302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dallas S.L., Prideaux M., Bonewald L.F. The osteocyte: an endocrine cell ... and more. Endocr. Rev. 2013;34:658–690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3785641</ArticleId>
            <ArticleId IdType="pubmed">23612223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hemmatian H., Conrad S., Furesi G., Mletzko K., Krug J., Faila A.V., Kuhlmann J.D., Rauner M., Busse B., Jahn-Rickert K. Reorganization of the osteocyte lacuno-canalicular network characteristics in tumor sites of an immunocompetent murine model of osteotropic cancers. Bone. 2021;152</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34174502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosen L.S., Wesolowski R., Baffa R., Liao K.H., Hua S.Y., Gibson B.L., Pirie-Shepherd S., Tolcher A.W. A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors. Invest. New Drugs. 2020;38:120–130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30887250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu J., Siebel C.W., Schilling L., Canalis E. An antibody to Notch3 reverses the skeletal phenotype of lateral meningocele syndrome in male mice. J. Cell. Physiol. 2020;235:210–220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6778702</ArticleId>
            <ArticleId IdType="pubmed">31188489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Canalis E., Yu J., Schilling L., Yee S.P., Zanotti S. The lateral meningocele syndrome mutation causes marked osteopenia in mice. J. Biol. Chem. 2018;293:14165–14177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6130932</ArticleId>
            <ArticleId IdType="pubmed">30042232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pajevic P.Divieti. New and old osteocytic cell lines and 3D models. Curr. Osteoporos. Rep. 2020;18:551–558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32794140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delgado-Calle J., Anderson J., Cregor M.D., Hiasa M., Chirgwin J.M., Carlesso N., Yoneda T., Mohammad K.S., Plotkin L.I., Roodman G.D., Bellido T. Bidirectional notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma. Cancer Res. 2016;76:1089–1100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4775415</ArticleId>
            <ArticleId IdType="pubmed">26833121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giuliani N., Ferretti M., Bolzoni M., Storti P., Lazzaretti M., Dalla P.B., Bonomini S., Martella E., Agnelli L., Neri A., Ceccarelli F., Palumbo C. Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia. 2012;26:1391–1401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22289923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDonald M.M., Reagan M.R., Youlten S.E., Mohanty S.T., Seckinger A., Terry R.L., Pettitt J.A., Simic M.K., Cheng T.L., Morse A., Le L.M.T., Abi-Hanna D., Kramer I., Falank C., Fairfield H., Ghobrial I.M., Baldock P.A., Little D.G., Kneissel M., Vanderkerken K., Bassett J.H.D., Williams G.R., Oyajobi B.O., Hose D., Phan T.G., Croucher P.I. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. Blood. 2017;129:3452–3464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5492093</ArticleId>
            <ArticleId IdType="pubmed">28515094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toscani D., Palumbo C., Dalla P.B., Ferretti M., Bolzoni M., Marchica V., Sena P., Martella E., Mancini C., Ferri V., Costa F., Accardi F., Craviotto L., Aversa F., Giuliani N. The proteasome inhibitor bortezomib maintains osteocyte viability in multiple myeloma patients by reducing both apoptosis and autophagy: a new function for proteasome inhibitors. J. Bone Miner. Res. 2016;31:815–827.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26551485</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
